Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid L

• Status: Recruiting
• Trial end date: 2024-11-01

Summary

The primary objective of this study is to compare the efficacy of magrolimab + azacitidine versus venetoclax + azacitidine in adults with previously untreated TP53 mutant acute myeloid leukemia (AML) who are appropriate for non-intensive therapy as measured by overall survival (OS).

• Phase: Phase 3

Details

• Lead Sponsor: Gilead Sciences
• Treatments: Azacitidine; Cytarabine; Daunorubicin; Idarubicin; Magrolimab; Ophthalmic Solutions; Venetoclax